

## Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update

July 18, 2017

CANTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 9, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

## **Conference Call Information:**

To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International) and refer to Conference ID: 5785-1943. An audio webcast will be accessible from the Investor Relations section of the Company's website: <a href="http://www.collegiumpharma.com/">http://www.collegiumpharma.com/</a>. An archived webcast will be available on the Company's website approximately two hours after the event.

## About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx<sup>®</sup> technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

## About Xtampza ER

Xtampza<sup>®</sup> ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:
Alex Dasalla
adasalla@collegiumpharma.com



Collegium Pharmaceutical, Inc